Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
8.07
-0.33 (-3.93%)
At close: Mar 28, 2025, 4:00 PM
7.77
-0.30 (-3.71%)
Pre-market: Mar 31, 2025, 8:53 AM EDT
Intellia Therapeutics Analyst Ratings
Total Analysts
18
Consensus Rating
Buy
Price Target
$39.44
Upside
+388.72%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +271.75% | Mar 5, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $90 → $50 | Strong Buy | Maintains | $90 → $50 | +519.58% | Mar 4, 2025 |
| Barclays | Barclays | Buy Maintains $55 → $26 | Buy | Maintains | $55 → $26 | +222.18% | Feb 28, 2025 |
| Citigroup | Citigroup | Hold Maintains $12 → $14 | Hold | Maintains | $12 → $14 | +73.48% | Feb 28, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $60 → $50 | Buy | Maintains | $60 → $50 | +519.58% | Feb 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $91 → $68 | Strong Buy | Maintains | $91 → $68 | +742.63% | Feb 28, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades $45 → $13 | Buy → Hold | Downgrades | $45 → $13 | +61.09% | Feb 28, 2025 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $56 → $11 | Buy → Hold | Downgrades | $56 → $11 | +36.31% | Jan 27, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $12 | Hold | Maintains | $20 → $12 | +48.70% | Jan 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $60 → $40 | Buy | Maintains | $60 → $40 | +395.66% | Jan 13, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $70 → $60 | Buy | Maintains | $70 → $60 | +643.49% | Jan 10, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $70 → $50 | Buy | Maintains | $70 → $50 | +519.58% | Jan 10, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $90 | Strong Buy | Maintains | $90 | +1,015.24% | Nov 19, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $80 → $70 | Buy | Maintains | $80 → $70 | +767.41% | Nov 18, 2024 |
| Wedbush | Wedbush | Hold Reiterates $14 | Hold | Reiterates | $14 | +73.48% | Nov 18, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $88 → $91 | Strong Buy | Maintains | $88 → $91 | +1,027.63% | Nov 18, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.